A5039194864- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Botulinum Toxin and Related Neurological Disorders
- Ophthalmology and Eye Disorders
- Neurological Disorders and Treatments
- Olfactory and Sensory Function Studies
- Pain Management and Placebo Effect
- Cardiovascular Syncope and Autonomic Disorders
- Neuroscience and Neuropharmacology Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Acute Ischemic Stroke Management
- Medical Imaging Techniques and Applications
- Transcranial Magnetic Stimulation Studies
- Vagus Nerve Stimulation Research
- Pain Mechanisms and Treatments
- Advanced MRI Techniques and Applications
- Pain Management and Treatment
- Biomedical and Chemical Research
- Neurological disorders and treatments
- Biochemical effects in animals
- S100 Proteins and Annexins
- Neuroscience of respiration and sleep
- Stroke Rehabilitation and Recovery
- Psychosomatic Disorders and Their Treatments
Neurology Center of Southern California
2010-2024
Alzheimer’s Disease Neuroimaging Initiative
2015
Brigham and Women's Hospital
2015
University of Michigan
2015
University of Pittsburgh
2015
Providence Hospital
2015
Pfizer (United Kingdom)
2015
Pfizer (United States)
2015
University College London
2015
Ixico (United Kingdom)
2015
Objective.— To compare the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX ® : Allergan, Inc.) divalproex sodium (DVPX; DEPAKOTE Abbott Laboratories) as prophylaxis in reducing disability impact associated with migraine. Background.— There is a need for effective, well‐tolerated prophylactic treatment Design/Methods.— This was randomized, double‐blind, single‐center prospective study. Fifty‐nine patients received either BoNTA 100 U/placebo‐DVPX bid or placebo‐BoNTA/DVPX 250 mg...
<i>Objective:</i> To assess the safety of tissue-type plasminogen activator (t-PA) plus clomethiazole in patients with acute ischemic stroke and determine feasibility combination therapy. <i>Background:</i> Clomethiazole is a neuroprotectant that appeared to improve outcome clinical deficits major (total anterior circulation syndrome [TACS]) previous study, Acute Stroke Study (CLASS). Combining such as thrombolysis may augment beneficial effects two agents. CLASS–t-PA (CLASS-T) was pilot...
To study the efficacy and safety of lasmiditan for acute treatment migraine in patients using preventive medications.While has been proven to be an effective migraine, its effectiveness not examined when used concurrently with preventives.SAMURAI SPARTAN were similarly designed, double-blind, phase 3, placebo-controlled studies 18 years or older 3 8 attacks per month. Patients randomized treat a attack oral 50 mg (SPARTAN only), 100 mg, 200 placebo. Migraine preventives allowed as long doses...
Erenumab, a first-in-class monoclonal antibody targeting the calcitonin gene-related peptide pathway, was approved by US Food and Drug Administration in 2018 for prevention of migraine adults. There is limited data available on its impact real-world settings. The study aim to characterize treatment profiles, clinical outcomes, healthcare resource utilization patients prescribed erenumab from select major headache centers. A retrospective chart review with treated at least 3 months across...
Remote electrical neuromodulation (REN) is an acute treatment of migraine. The results from several studies in patients with episodic migraine suggest that REN effective and safe A recent pilot study provided initial support chronic as well.The current aimed to validate provide further evidence for the safety efficacy a large sample impacted by migraine.In this open-label, single-arm study, treated their headaches device (Nerivio, Theranica Bio-Electronics Ltd, Israel) 4 weeks. Participants...
Abstract Objective To evaluate long‐term reductions in acute headache medication (AHM) use with eptinezumab versus placebo patients prior preventive migraine treatment failures and overuse (MO). Background Preventive is recommended for whom AHMs have failed those who are using excessive amounts of AHM. MO may worsen symptoms people migraine; it a risk factor disease chronification and/or headache. Methods DELIVER was multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled,...
Abstract Objective To develop a multivariable model assessing factors predicting second‐dose response to eptinezumab treatment over weeks 13–24 in patients with migraine initially reporting suboptimal 1–12. Background Eptinezumab is monoclonal antibody used for prevention, administered every 12 weeks. In the PROMISE‐1 and PROMISE‐2 studies, first‐dose (≥50% monthly day [MMD] reduction 1–12) occurred ~50–60% of episodic (EM) chronic (CM), respectively. Methods This post hoc analysis included...
Abstract Background Patients with chronic migraine (CM) treated eptinezumab in the PROMISE-2 trial achieved greater reductions and headache frequency, impact, acute medication (AHM) use than did patients who received placebo. This post hoc analysis examines relationships between frequency changes AHM PROMISE-2. Methods was a double-blind, placebo-controlled conducted adults CM. were randomized to 100 mg, 300 or placebo, administered intravenously once every 12 weeks for up two doses....
Monday, April 27April 14, 2020Free AccessRimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase Trials (1609)Jack Schim, Susan Hutchinson, Richard Lipton, Elyse Stock, Alexandra Thiry, Charles Conway, Christopher Jensen, Beth Morris, Vladimir Coric, Robert CroopAuthors Info & AffiliationsApril 2020 issue94 (15_supplement)https://doi.org/10.1212/WNL.94.15_supplement.1609 Letters the Editor
Objective: This study aimed to assess the safety and effectiveness of remote electrical neuromodulation (REN) in people with chronic migraine. Background: REN (Nerivio®, Theranica Bio-Electronics LTD., Israel) is an acute treatment for Results from several studies patients episodic migraine suggest that effective safe In addition, a recent pilot provided initial support migraine, but additional data needed establish this population. Design/Methods: open-label, single-arm study, treated their...
May 8, 2019April 9, 2019Free AccessEptinezumab Increases Days Free from Canonical Migraine-Associated Symptoms Within 1 Month of Treatment in Patients with Chronic Migraine (P4.10-024)Jack Schim, Peter Goadsby, Eric Kassel, David Biondi, Joe Hirman, and Roger CadyAuthors Info & AffiliationsApril 2019 issue92 (15_supplement)https://doi.org/10.1212/WNL.92.15_supplement.P4.10-024 Letters to the Editor
To evaluate changes in days of acute headache medication (AHM) use among patients with medication-overuse (MOH) from the PROMISE-2 trial.